Pegaspargase is under clinical development by Les Laboratoires Servier and currently in Phase III for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase III drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pegaspargase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pegaspargase overview
Pegaspargase (Oncaspar) is a modified version of the enzyme L-asparaginase, derived from E.coli, acts as anti-neoplastic agent. The product is based on customized PEGylation linker technology. It is formulated as pegylated injectable solution and lyophilized powder for intramuscular and intravenous route of administration. It is used for the first line treatment of acute lymphoblastic leukemia (ALL) as well as for the treatment of acute lymphoblastic leukemia in patients hypersensitive to native forms of L-asparaginase, in conjunction with other chemotherapeutic agents. Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. Pegaspargase was under development for the treatment of chronic myeloid leukemia, solid tumors, relapsed or refractory T-cell lymphomas and lymphomas including non-Hodgkin lymphoma.
The drug candidate is under development for the treatment of B cell acute lymphoblastic leukemia, malignant lymphoma, down syndrome, B lineage lymphoblastic lymphoma.
See Also:
The drug candidate (freeze dried) was under development for the treatment T-Cell lymphomas and chronic myelocytic leukemia.
Les Laboratoires Servier overview
Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. It invests a substantial amount of revenue in R&D, particularly in France and Hungary. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, France
For a complete picture of Pegaspargase’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
